Celexa withdrawal. Celexa withdrawal side effects, withdrawal warnings, withdrawal precautions, withdrawal adverse effects, overdose, withdrawal symptoms and Celexa natural alternatives. Before you begin the spiral down with Celexa, try giving your body what it really wants.

Celexa

Celexa Withdrawal Side Effects

Read Celexa side effects defined. Note: These Celexa side effects may also be Celexa withdrawal side effects.
Click here

August 2, 2007 - DNA breakthrough predicting adverse reactions or effectiveness with taking Celexa. Research scientists are continuing to unravel what antidepressants are doing within the body but more importantly, predicting the onset of adverse reactions. With the vast majority of individuals reacting to Celexa with adverse reactions, the prediction of who will react and how quickly they will react needs to be researched further.

It is known, all people will react to Celexa in a negative manner at some point in time but who will react as soon as they take the medication, usually within one week. The goal of science or the pharmaceutical company is to design a drug specifically for the masses, but it is known, without question, that will not happen with with this new DNA information.

Celexa Antidepressant

Celexa hydrobromide is a highly selective and potent serotonin (5-hydroxytryptamine 5-HT) reuptake inhibitor with minimal effects on the neuronal reuptake of norepinephrine (NE) and dopamine (DA). The ability 
of Celexa to potentiate serotonergic activity in the central nervous system via inhibition of the neuronal reuptake of serotonin is thought to be responsible for its antidepressant action. Tolerance to the inhibition of serotonin reuptake is not induced by long term (14 days) treatment of rats with Celexa.

Celexa has no or very low affinity for a series of receptors including serotonin 5-HT_1A, 5-HT₂, dopamine D₁, and D₂, a₁-, a₂-, b-adrenergic, histamine H₁, muscarinic cholinergic, benzodiazepine, gamma aminobutyric acid (GABA) and opioid receptors.

Pharmacokinetics

Absorption
Following the administration of a single oral dose of Celexa (40 mg) to healthy male volunteers, peak blood levels occurred at about 4 hours (range 1 to 6 hours). The absolute bioavailability of Celexa was about 80% (range 52 to 93%) relative to an intravenous dose. Absorption was not affected by food.

Distribution
After intravenous infusion in healthy male volunteers the apparent volume of distribution (V_d)b was about 12 L/kg (range 9-17 L/kg), indicating a pronounced tissue distribution: (V_d)b oral was about 17 L/kg (range 14-17 L/kg). The binding of Celexa and its demethylated metabolites to human plasma proteins is about 80%.

Steady-state
The single- and multiple dose pharmacokinetics of Celexa are linear and dose proportional in a dose range of 10 to 60 mg/day. Steady-state plasma levels are achieved in patients in 1-2 weeks. At a daily dose of 40 mg, the average plasma concentration is about 83 ng/mL (n=114) with a range from 30 to 200 ng/mL. Celexa does not accumulate during long term treatment. A clear relationship between Celexa plasma levels and therapeutic response or side effects has not been established.

Metabolism
Celexa is metabolized in the liver to demethylCelexa (DCT), didemethylCelexa
 (DDCT), Celexa N-oxide and a deaninated propionic acid derivative. In vitro studies show that DCT, DDCT and Celexa-N-oxide also inhibit the neuronal reuptake of serotonin but are less selective and less potent than the parent compound and are of minor clinical importance. Unchanged Celexa is the predominant compound in plasma. In vitro studies indicated that the biotransformation of Celexa to its demethyl metabolites depends on both CYP2C19 and CYP3A4, with a small contribution from CYP2D6.

Elimination
The elimination half life of Celexa (t_1/2b) is approximately 37 hours (range 30-42 hours) which allows recommendation of once-daily dosing. The systemic Celexa plasma clearance (Cl₅) is 0.33 L/min. Celexa
is eliminated primarily via the liver (85%) and the remainder via the kidneys; approximately 12% (range 6-21%) of the daily dose is excreted in urine as unchanged Celexa.

Special Populations:   Back to top of page

Elderly Patients
Elderly patients (4 males and 7 females aged 73-90 years), received a 20 mg/day dose of Celexa for 3-4 weeks. In the elderly, steady state plasma levels were elevated (106 ng/mL), half-life prolonged (1.5-3.75 days) and clearance decreased (0.08-0.3 L/min). Elevation of Celexa plasma levels occurred at an earlier age in females than in males, In this population, lower doses and a lower maximum dose of Celexa are recommended.

Reduced Hepatic Function
The pharmacokinetics of Celexa were compared in patients with reduced hepatic function (3 female and 6 male patients aged 41-60 years) to those seen in 12 healthy male volunteers (aged 21-43 years), In patients with reduced hepatic function the half-life of Celexa was approximately doubled (83 hours versus 37 hours), steady state Celexa concentrations increased by 61% and oral clearance decreased by 37%. Consequently the use of Celexa in patients with reduced hepatic function should be approached with caution and lower maximal doses should be prescribed (see PRECAUTIONS and DOSAGE AND ADMINISTRATION).

Reduced Renal Function
In patients with mild to moderate reduction of the renal function (4 females and 3 males, aged 30-55 years), Celexa was being eliminated more slowly than in 12 healthy male volunteers (aged 21-43 years), half-lives being 49 hours versus 37 hours. However, mild to moderate renal impairment had no major influence on the kinetics of Celexa. At present, no information is available for chronic treatment of patients with severely reduced renal function (creatinine clearance <20 mL/min). 

Indications and Clinical Use   Back to top of page

Celexa hydrobromide is indicated for the symptomatic relief of depressive illness.

The relapse rate was significantly lower in Celexa-treated patients than in placebo-treated patients in two placebo-controlled studies, that were conducted over a 24-week period in patients who responded to 6 or 8 weeks of acute treatment with Celexa (see CLINICAL TRIALS under ACTION AND CLINICAL PHARMACOLOGY.) Nevertheless, the physician who elects to use Celexa for extended periods should periodically reevaluate the long-term usefulness of the drug for the individual patient.

Contraindications   Back to top of page

Monoamine Oxidase Inhibitors
In patients, receiving selective serotonin reuptake inhibitors (SSRIs) in combination with a monoamine oxidase inhibitor (MAOI), there have been reports of serious, sometimes fatal, reactions including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes, including extreme agitation progressing to delirium and coma. These reactions have also been reported in patients who have recently discontinued SSRI treatment and have been started on a MAOI. Some cases presented with features resembling serotonin syndrome. Therefore, it is recommended that Celexa should not be used in combination with a MAOI or within 14 days of discontinuing treatment with a MAOI. Similarly, at least 14 days should elapse after discontinuing Celexa treatment before starting a MAOI.

Precautions   Back to top of page

Suicide
The possibility of a suicide attempt is inherent in depression and may persist until remission occurs. Therefore, high risk patients should be closely supervised throughout therapy with Celexa hydrobromide and consideration should be given to the possible need for hospitalization. In order to minimize the opportunity for overdosage, prescription for Celexa should be written for the smallest quantity of drug consistent with good patient management.

Activation of Mania/Hypomania
In placebo-controlled trials with Celexa, some of which included patients with bipolar disorder, mania/hypomania was reported in 0.1% of 1027 patents treated with Celexa versus none of the 426 patients treated with placebo. Activation of mania/hypomania has also been reported in a small proportion of patients with major affective disorders treated with other marketed antidepressants. If a patient enters a manic phase, Celexa should be discontinued.

Seizures
Celexa has not been systematically evaluated in patients with a seizure disorder. These patients were excluded from clinical studies during the premarketing testing of Celexa. In clinical trials, seizures occurred in 0.25% of patients treated with Celexa and in 0.23% patients treated with placebo. Like other antidepressants, Celexa should be used with caution in patients with a history of seizure disorder.

Serotonin Syndrome
Rarely, the occurrence of serotonin syndrome has been reported in patients receiving SSRIs. A combination of symptoms, possibly including agitation, confusion, tremor, myoclonus and hyperthermia, may indicate the development of this condition.

5-HT₁ Agonists
There have been rare postmarketing reports describing patients with weakness, hyperreflexia and incoordination, following the concomitant use of a SSRI and the antimigraine drug sumatriptan, a 5-HT₁ agonist. Such interaction should be considered if Celexa is to be used in combination with a 5-HT₁ agonist.

Hyponatremia
Hyponatremia and SIADH (syndrome of inappropriate antidiuretic hormone secretion) have been reported with Celexa use as a rare adverse event.

Pregnancy and Nursing Mothers
The safety of Celexa during pregnancy and lactation has not been established. Therefore, Celexa should not be used during pregnancy, unless, in the opinion of the physician, the expected benefits to the patient markedly outweigh the possible hazards to the fetus. Celexa is excreted in human milk. Celexa should not be administered to nursing mothers unless, in the opinion of the treating physician, the expected benefits to the patient markedly outweigh the possible hazards to the child.

Pediatric Use
Safety and effectiveness in patients below the age of 18 have not been established.

Geriatric Use
In premarketing clinical trials, 800 elderly patients (>=65 years of age) have been treated with Celexa. Of these patients 298 were >=75 years old. In a pharmacokinetic study (n=11, age 73 to 90 years), clearance was substantially decreased and half-life prolonged (see PHARMACOKINETICS). In a 6-week placebo-controlled study, approximately equal numbers of patients received Celexa at 20 or 30 mg per day, as the final dose. In about 5% of patients, the final dose was 10 mg per day (see CLINICAL TRIALS). Consequently, elderly patients should be administered lower doses and a lower maximum dose.

Hepatic Impairment
Celexa clearance was significantly decreased and plasma concentrations, as well as elimination half-life significantly increased (see PHARMACOKINETICS). Consequently, the use of Celexa in hepatically impaired patients should be approached with caution and a lower maximum dosage is recommended.

Renal Impairment
No dosage adjustment is needed in patients with mild to moderate renal impairment. To date, no information is available on the pharmacokinetic or pharmacodynamic effects of Celexa in patients with severely reduced renal function (creatinine clearance <20 mL/min).

Use in Patients with Cardiac Disease
Celexa has not been systematically evaluated in patients with a recent history of myocardial infarction or unstable heart disease. Patients with these diagnoses were generally excluded from clinical trials during the drugs premarketing assessment. However, the electrocardiograms of patients, who received Celexa
 in clinical trials, indicate that Celexa was not associated with the development of clinically significant ECG abnormalities.

In clinical trials, Celexa caused small but statistically significant decreases in heart rate (see ECG under ADVERSE REACTIONS) Consequently, caution should be observed when Celexa is initiated in patients with pre-existing slow heart rate.

Use in Diabetic Patients
Celexa has not been systematically evaluated in diabetic patients since diabetes constituted an exclusion criterion. Although 13 patients did receive insulin during the studies, this number is too small to determine whether Celexa affects the response to insulin. Rare events of hypoglycemia were reported. Celexa
should be used with caution in diabetic patients on insulin or other antidiabetic drugs.

Interference with Cognitive and Motor Performance
In studies in normal volunteers, Celexa in doses of 40 mg/day did not impair cognitive function or psychomotor performance. However, psychotropic medications may impair judgment, thinking or motor skills. Consequently, patients should be cautioned against driving a car or operating hazardous machinery until they are reasonably certain that Celexa does not affect them adversely.

Electroconvulsive Therapy (ECT)
The safety and efficacy of the concurrent use of Celexa and ECT have not been studied.

Abrupt Discontinuation   Back to top of page

After 8 weeks of treatment with Celexa, abrupt discontinuation of treatment caused a higher incidence of anxiety, emotional indifference, impaired concentration, headache, migraine, paresthesia, and tremor than was seen in patients who continued on Celexa. These symptoms are not indicative of addiction.

Although it is not known whether gradual discontinuation will prevent the discontinuation symptoms, it is recommended that the dosage of Celexa should be tapered off over 1 to 2 weeks.

Additional Adverse Events Observed During the Premarketing Evaluation of Celexa
   Back to top of page

The events listed below include all adverse events that were reported in the overall development program of Celexa (n=3652). All reported events are included except those already listed in Table 1 and those events which occurred in only one patient. It is important to emphasize that, although the events reported occurred during treatment with Celexa, they were not necessarily caused by it. The events are enumerated using the following criteria: frequent: adverse events that occurred on one or more occasions in at least 1/100 patients; infrequent: adverse events that occurred in less than 1/100 patients but at least in 1/1000 patients; rare: adverse events that occurred in fewer than 1/1000 patients.

Body as a Whole - General Disorders
Frequent: Influenza-like symptoms, nonpathological trauma, pain. Infrequent: Alcohol intolerance, allergic reaction, allergy, chest pain, edema, hot flushes, leg pain, malaise. rigors, syncope. Rare: Peripheral edema, sudden death, traumatic injury.

Cardiovascular Disorders
Frequent: Postural hypotension, tachycardia. Infrequent: Angina pectoris, arrhythmia. bradycardia, cardiac failure, cerebrovascular disorders, edema dependent, extrasystoles, flushing, hypertension, hypotension, myocardial infarction, myocardial ischemia, peripheral ischemia. Rare: Aggravated hypertension, bundle branch block, cardiac arrest, coronary artery disorder, ECG abnormal, heart disorder, phlebitis, supraventricular extrasystoles.

Central and Peripheral Nervous System Disorders
Frequent: Migraine, paraesthesia. Infrequent: Abnormal gait, ataxia, convulsions, dysphonia, dystonia, extrapyramidal disorder, hyperkinesia, hypertonia, hypoesthesia, hypokinesia, involuntary muscle contractions, leg cramps, neuralgia, speech disorder, vertigo Rare: Abnormal coordination, convulsions grand mal, hyperesthesia, ptosis, sensory disturbance, stupor.

Collagen Disorders
Rare: Rheumatoid arthritis.

Endocrine Disorders
Rare: Goiter, gynecomastia, hypothyroidism.

Gastrointestinal System Disorders
Frequent: Flatulence. Infrequent: Colitis, dental abscess, dysphagia, eructation, gastritis, gastroenteritis, gastrointestinal disorder (not specified), hemorrhoids, increased saliva, teeth-grinding, toothache. Rare: Appendicitis, esophagitis, gastric ulcer, gastroesophageal reflux, gingivitis, stomatitis, tooth disorder, ulcerative stomatitis.

Hematopoietic and Lymphatic Disorders
Infrequent: Anemia, epistaxis, leukocytosis, purpura. Rare: Coagulation disorder, gingival bleeding, granuloytopenia, hematoma, leukopenia, lymphadenopathy, lymphocytosis, pulmonary embolism.

Liver and Biliary System Disorders.
Infrequent: Cholecystitis, cholelithiasis, increased gamma-GT, increased SGPT. Rare: Bilirubinemia, increased SGOT, jaundice.

Metabolic and Nutritional Disorders
Frequent: Weight decrease, weight increase. Infrequent: Leg edema, xerophthalmia. Rare: Dehydration, edema, hypoglycemia, hypokalemia, increased alkaline phosphatase, obesity, thirst.

Musculo-Skeletal System Disorders
Infrequent: Arthralgia, arthritis, arthrosis, dystonia, muscle weakness, myalgia. Rare: Bone disorder, bursitis, osteoporosis, tendon disorder.

Neoplasm
Rare: Breast neoplasm malignant female.

Psychiatric Disorders
Frequent: Abnormal dreaming, aggravated depression, amnesia, apathy, confusion, depression, impaired concentration, increased appetite, sleep disorder, suicide attempt. Infrequent: Abnormal thinking, aggressive reaction, delusion, depersonalization, drug abuse, drug dependence, emotional lability, euphoria, hallucination, increased libido, manic reaction, neurosis, paranoid reaction, paroniria, psychosis, psychotic depression. Rare: Catatonic reaction, hysteria, personality disorder.

Reproductive Disorders, Female
Infrequent: Amenorrhea, breast pain, lactation nonpuerperal, menorrhagia, menstrual disorder, premenstrual syndrome, salpingitis, unintended pregnancy, vaginal dryness, vaginitis. Rare: Breast enlargement, vaginal hemorrhage.

Reproductive Disorders, Male
Infrequent: Penis disorder, prostatic disorder, testis disorder.

Resistance Mechanism Disorders
Infrequent: Abscess, fungal infection, herpes simplex infection, otitis media, viral infection. Rare: Bacterial infection, moniliasis, sepsis.

Respiratory System Disorders
Infrequent: Bronchitis, coughing, dyspnea, pneumonia. Rare: Asthma, bronchospasm, increased sputum, laryngitis, pneumonitis, respiratory disorder.

Skin and Appendage Disorders
Frequent: Pruritus, rash. Infrequent: Acne, alopecia, dermatitis, dry skin, eczema, photosensitivity reaction, psoriasis, rash erythematous, rash maculo-papular, skin discoloration, urticaria. Rare: Cellulitis, decreased sweating, hypertrichosis, melanosis, pruritus ani.

Special Senses, Vision, Hearing and Vestibular Disorders
Frequent: Abnormal accommodation. Infrequent: Conjunctivitis, earache, eye pain, mydriasis, taste perversion, tinnitus. Rare: Eye abnormality, keratitis, photophobia.

Urinary System Disorders
Frequent: Polyuria. Infrequent: Abnormal urine, cystitis, hematuria, micturition frequency, urinary incontinence, urinary retention, urinary tract infection. Rare: Dysuria, facial edema, oliguria, renal calculus, renal pain.

Events Observed During the Post-Marketing Evaluation of Celexa
   Back to top of page

It is estimated that approximately 8 million patients have been treated with Celexa since market introduction. The following adverse events have been reported to be temporarily associated with Celexa treatment in at least 3 patients and are not described elsewhere in labeling.

Abnormal hepatic function, aggravated condition, aggravated migraine, angioedema, asthma, choreoathetosis, decreased drug level, decreased prothrombin time, dyskinesia, eosinophilia, erythema multiforms, gynecological problems, hepatitis, hyperprolactinemia, hyponatremia, increased drug level, increased prothrombin time, mydriasis, neuroleptic malignant syndrome, neuropathy, pancreatitis, pancytopenia, postural hypotension, serotonin syndrome, SIADH, spontaneous abortion/fetal death, thrombocytopenia, ventricular arrhythmia, Torsade de pointes, withdrawal syndrome.

Back to top of page

Celexa - Side Effects Defined

1. Anorexia – No longer having a desire to eat.
    

2. Apothous Stomatitis – Painful red and swollen open sores on a mucus membrane of the mouth commonly called a canker sore.
    

3. Ataxia – Loss of the ability to move the body with coordination.
    

4. Arterial Fibrillation – A condition of abnormal twitching of the muscles in the blood vessels that moves the oxygenated blood from the heart to the rest of the body.  The unusual twitching is rapid and irregular and replaces the normal rhythm of contraction of the muscle, which sometimes causes a lack of circulation and pulse.
    

5. Blood Cholesterol Increased – An abnormal condition where there is a greater amount in the blood of the oily/fatty substances known as cholesterol.   Cholesterol is a necessary part of living cells (along with proteins and carbohydrates).  Because cholesterol only slightly dissolves in water, it can build up on the walls of the blood vessels, therefore blocking/decreasing the amount of blood flow, which causes blood pressure to go up.  If not corrected, this condition is associated with coronary artery disease.
    

6. Blood Creatinine Increased – A greater than normal number of creatinine or muscular chemical waste molecules in the blood.  Creatinine plays a major role in energy production in muscles.  Since creatinine levels are normally maintained by the kidneys, Blood Creatinine Increased is an indicator of kidney malfunction or failure.
    

7. Blood in Stool – The blood that is in your bowel movement usually comes from any place along your digestive tract (from your mouth to your anus).  The stool can appear black and foul-smelling (usually from the upper part of your digestive tract) or red or maroon-colored (usually from the large intestine area).  Hemorrhoids are the usual cause for blood in the bowels.

8.       Bundle Branch Block Right – These are specialized cells in the upper right heart chamber and are the heart’s pacemaker.  They send electrical signals to the heart that keeps it beating or contracting regularly.  Normally the signal goes to the lower heart chambers at the same time through the bundle of His (hiss) on both the left and right sides of the heart, so the lower chambers contract at the same time.  When the bundle is damaged on the right side, the signal does not fire at the same time as the left, which changes the pace of blood flow.  This can lead to a person fainting.

9. Cardiac Failure – A heart disorder where the heart does not function as usual and may completely stop working.
    

10. Cardiac Failure Congestive – The body is asking for the heart to supply more blood than it is capable of producing and maintaining.  Normally, a body can tolerate an increased amount of work for quite some time.  The condition is characterized by weakness, shortness of breath, and a fluid build-up in the body tissues causing swelling.
     

11. Cold Sweat – The skin is clammy and moist and you feel chilled.  This is a reaction to a shock or pain as well as to fear and nervousness.
     

12. Colitis – A condition where the large intestine becomes irritated from the use of the drug.
     

13. Coronary Artery Disease – A condition where the blood vessels that mainly carry the blood away from the heart become clogged up or narrowed usually by fatty deposits.  The first symptom is pain spreading from the upper left body caused by not enough oxygen reaching the heart.
     

14. Dehydration – An extreme loss of water from the body or the organs of the body as in sickness or not drinking enough fluids.
     

15. Diplopia – The condition where a person is looking a one object and instead of normally seeing just the one object he sees two.  This is also call double vision.
     

16. Diverticulitis – There are pouches or sacs on the inside of the intestines that look like fingers.  This increases the area for the body to absorb nutrients as they pass through the intestines.  These sacs become irritated and swollen and end up trapping waste that would normally be eliminated, causing pain and constipation.
     

17. Dysarthria – The inability to control the mouth muscles when forming words so the words are not clearly spoken and heard.
     

18. Dyslipidemia – The normal fat metabolism in the blood is interfered with.
     

19. Dysphagia – Trouble swallowing or the inability to swallow.
     

20. Ecchymosis – When a blood vessel breaks and creates a purple discoloration of the skin.
     

21. Edema – An abnormal build up of excess fluids in the cells, tissues, and the spaces between the tissues creating swelling.
     

22. Edema Peripheral – The abnormal build up of fluids in the tissues of the ankles and legs causing painless swelling in the legs, ankles, and feet.  If you squeeze the swollen area it leaves an indentation on the skin for a few minutes.
     

23. Ejaculation Delayed – The man is not able to release sperm either during sexual intercourse or with manual stimulation in the presence of his sexual partner in spite of his wish to do so.
     

24. Ejaculation Dysfunction – A condition where the man has one or more of the following symptoms:  He is not able to have an erection, not able to have an orgasm, has a decreased interest in sex, is sexually inhibited, or it is painful to ejaculate sperm.
     

25. Erectile Dysfunction – Incapable of having sexual intercourse.  Even though a man desires sex he is inhibited in his sexual activity and is unable to have or maintain an erection of the penis.
     

26. Erythema – a skin redness caused by the swelling with blood of the tiny blood vessels of the skin as in burns.
     

27. Erythematous Rash – Redness of the skin from the swelling of the tiny blood vessels with skin irritation (itching, burning, tingling, pain) and breakouts (eruptions).

28. Esophageal Stenosis Acquired – The tube that moves food from the mouth to the stomach narrows.
     

29. Exfoliative Dermatitis – The unusual and not normal condition of scaling and shedding of the skin cells.  The skin is usually red colored.
     

30. Face Edema – The tissues of the face become swollen.
     

31. Feeling Jittery – A physical sensation of nervous unease.
     

32. Gastric Irritation – An inflamed and sore stomach.
     

33. Gastric Ulcer – An open, irritated, and infected sore in the wall of the stomach.
     

34. Gingivitis – Sore, swollen and red gums in the mouth that bleed easily.
     

35. Glaucoma – The delicate nerve to the eye, the optic nerve, becomes easily damaged with the build-up of excess fluid pressure within the eyeball.  The first sign of glaucoma is loss of peripheral (side) vision.  It can progress to total blindness.
     

36. Hepatic Steatosis – Excessive amounts of fat in the liver.
     

37. Hyperhidrosis – The triggering of an excess of sweat being produced on the soles of the feet, the palms, or the underarms which can cause embarrassment or losing grip on a pen or other items.
     

38. Hyperkeratosis – An abnormal enlargement of the skin tissues causing the skin cells to increase in size.
     

39. Hyperlipidemia – An abnormally high number of fat cells in the blood.
     

40. Hypertriglyceridemia – Too many triglycerides in the blood. 

Triglycerides are three fatty acids bound together in one molecule stored by the body and available to create high levels of energy when used. 

41. Hypoesthesia – A partial loss of sensation or general loss of awareness.
     

42. Impaired Gastric Emptying – The contents of the stomach are not passed into the intestines as normal due to the stomach losing the muscular strength to do so.
     

43. Increased White Blood cell Count – This is an increase in the number of cells in the blood that are responsible for the removal of bacteria and other unwanted particles.  They fight disease and infection by enclosing foreign particles and removing them.  An example of a disease that would increase white blood cell count would be Leukemia.
     

44. Insomnia – Not able to fall asleep or sleeping for a shorter time than desired, thus not being able to properly rest and feeling un-refreshed.  As a result, a person can become irritable, have difficulty concentrating and feel a lack of energy.  This can be caused by stimulants such as by caffeine or drugs or by mental anxiety and stress.  Mental stress can be communicated and relieved.
     

45. Irritable Bowel Syndrome – A painful condition where the either the muscles or the nerves of the lower intestines, are not responding normally.  This results in an alternating condition of diarrhea followed by constipation, back and forth.
     

46. Keratoconjunctivitis Sicca – A condition where the outer coating of the eyeball is dry because of a decrease in the normal amount of tears in the eye.  As a result, the eyeball and inside of the eyelid thickens and hardens sometimes causing the vision to be less sharp.
     

47. Leukopenia – An unnaturally low number of white blood cells circulating in the blood.
     

48. Loose Stools – The bowel movement is runny instead of formed.
     

49. Lower Abdominal Pain – A hurtful irritation of the nerve endings in the area of the hipbones housing the lower digestive tract.  Pain usually means tissue damage.
     

50. Lymphadenopathy – The lymph nodes, where the immune cells are located, become larger than is normal because of a high concentration of white blood cells.
     

51. Macular Degeneration – The gradual loss of central vision, which is the sharpest vision while peripheral eyesight, is unaffected.
     

52. Maculopathy – An abnormal condition of the yellow spot of the eye, which is located in the center of the inner lining of the eyeball and connected to the main nerve to the eye and is responsible for sharp vision.
     

53. Mania – Unusually irrational, excessive and/or exaggerated behavior or moods ranging from enthusiasm, sexuality, gaiety, impulsiveness and irritability to violence.
     

54. Melena – Abnormally darkly colored stools as a result of hemorrhaging in the digestive tract where the blood has interacted with the digestive juices creating the dark color in the bowel movement.
     

55. Micturition Urgency – A sudden desire to urinate usually followed by leakage.
     

56. Mood Swings – An emotional shifting as from a state of happiness to a state of depression for a period of time.
     

57. Myocardial Infarction – The blood going to the heart is delayed or stopped causing middle muscle tissue in the heart wall to die.
     

58. Nasopharyngitis – Irritation, redness and swelling tissues in the nose and the tube leading from the mouth to the voice box as well as the tubes leading to the ears.
     

59. Nephropathy – An abnormally functioning or diseased kidney.
     

60. Nervousness – Jumpy, jittery, anxious, and troubled with an irritable temperament.
     

61. Night Sweats – The water-salt, waste product the skin releases is called sweat or perspiration.   With night sweats you become wide awake in the middle of the night shivering and cold and wet with your sheets/pajamas soaked in perspiration making it difficult to go back to sleep.
     

62. Nightmare – Dreams that make you afraid or leave feelings of fear, terror, and upset long after waking up.
     

63. Orgasm Abnormal – Unable to have an orgasm with normal sexual stimulation.
     

64. Oropharyngeal Swelling – A swelling in the area from the soft part of the roof of the mouth to the back of the mouth.
     

65. Pain in Extremity – A painful feeling in the legs, arms, hands, and feet.
     

66. Pharyngolaryngeal Pain – Pain in the area of the respiratory tract (organs of breathing) from the throat to the voice box and above the windpipe.
     

67. Photopsia – A condition where a person see lights, sparks or colors in front of your eyes.
     

68. Photosensitivity Reaction – An exaggerated sunburn reaction that is not normal in proportion to the amount of exposure to the light.
     

69. Pollakiuria – Urinating much more frequently than normal – as often as once every five to fifteen minutes.
     

70. Pressure of Speech – A condition where the individual cannot voice his ideas fast enough with the pressure of there being not enough time to say it.
     

71. Pruritic Rash – Extremely itchy, red, swollen bumps on the skin.
     

72. Pyrexia – Fever or the increase in body temperature that is usually a sign of infection.
     

73. Retinal Detachment – The thin layer lining the back of the eyeball (the retina) detaches from the back of the eyeball.  This thin layer is like the film of a camera because it sends the images a person views to the brain.  When it detaches it causes a reduced ability to see.
     

74. Rigors – Shivering or shaking of the body as if chilled, preventing normal responses.
     

75. Skin Ulcer – An open sore or infected skin eruption with swelling, redness, pus, and irritation.
     

76. Sleep Disorder – These are a list of sleep disorders such as teeth grinding, insomnia, jet lag, sleep walking, abnormally falling asleep during the middle of a conversation after a full night’s rest, uncontrolled body motions keeping one awake, etc.
     
77. Suicide, Completed – An attempted attack on oneself that is life threatening results in death.
     

78. Upper Respiratory Tract Infection – Where the organs of breathing near the mouth such as the nose and sinuses, become infected and are usually treated by antibiotics.
     

79. Urinary Hesitation – Hard to start or hard to continue emptying one’s bladder.
     

80. Urinary Incontinence – Urinating without intending to do so because of a weakening of the muscles in the hip area from the drug affecting the nerves or the drug blocking a persons thinking process.
     

81. Urinary Retention – The inability to completely empty the bladder despite having the urge to do so.  This can lead to infections or damage to the urinary organs.
     

82. Urine Flow Decreased – Dehydration of the body causing a lesser flow of urine than normal with the body reabsorbing the waste.
     

83. Urine Output Decreased – A condition where the output of urine produced in a 24-hour period is less than 500 ml.
     

84. Weight Decreased – Unintentional weight loss.

Other links www.aboutpsychdrugs.com The Road Back